Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

Abstract

Between October 1979 and January 1988, 101 patients with malignant lymphoma who failed initial induction treatment or relapsed received high-dose combination chemotherapy or chemoradiotherapy followed by infusion of autologous bone marrow. Twenty-eight of the 101 patients survive, 18 of whom are disease-free for a median of 26 (range, 12 to 66) months. The 5-year actuarial probabilities of survival, event-free survival (EFS), and relapse from transplantation were 20%, 11%, and 84%, respectively. Multivariate analysis showed that the likelihood of EFS was decreased among patients transplanted with a Karnofsky score of less than 80%. Recurrent lymphoma after transplant was the most important cause of treatment failure with 36 of 62 relapses occurring within 100 days from marrow infusion. Early, but not late relapse, was more frequent in patients transplanted for advanced lymphoma, and both early and late relapses were increased among patients with impaired pretransplant clinical performance or high-grade histology of lymphoma. Ten patients who relapsed post-transplant are alive, seven in remission. Further improvement of these results will require earlier transplantation, improved preparative regimens, or early posttransplant therapy.

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin

“…5,7 Resolution of these issues is complicated by the fact that only limited data are available. [5][6][7][8][9][10][11][12][13][14] Additionally, many studies of high-dose therapy and transplantation in low-grade NHL have included cases of mixed cell follicular NHL, 5,11 a disorder which may not be a classical low-grade lymphoma. [15][16][17] To clarify the role of high-dose therapy in conjunction with stem cell transplantation, this report summarizes our results using autologous or allogeneic bone marrow or stem cell transplantation in patients with follicular small cleaved cell lymphoma (SCCL).…”

Phase I-II Trial of Foscarnet for Prevention of Cytomegalovirus Infection in Autologous and Allogeneic Marrow Transplant Recipients

“…The methods of pretransplant conditioning and posttransplant care have been described [21,22]. Allogeneic transplant recipients were given cyclosporine plus a short course of methotrexate as GVHD prophylaxis [20].…”

Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?

“…These patients have a poor prognosis, even with autoSCT, [46][47][48][49] although recently a number of groups have demonstrated that autoSCT can effectively salvage about 50% of patients sensitive to second-line chemotherapy. [50][51][52] Preliminary data suggest that alloSCT may be effective for patients with induction failure, 19,31 although the effect of chemosensitivity has not been formally assessed in this population.…”